Table 2. Clinical and pathological characteristics of the patients.

Variable	No. (%) or variable unit	3-year DSS (95% CI)	P-value
Age at surgery, year, median (range)	52 (24–87)		0.162
<52	55 (49.5)	70.3 (57.7–83.0)
⩾52	56 (50.5)	52.3 (35.8–68.8)
BMI, kg m−2, median (range)	22.6 (16–37)		0.881
<22.6	55 (49.5)	60.2 (45.3–75.1)
⩾22.6	56 (50.5)	63.8 (48.9–78.7)
Number of LNs, n, median (range)	21 (8–55)		0.01
<21	55 (49.5)	48.1 (33.0–63.2)
⩾21	56 (50.5)	78.6 (66.4–90.8)
LNM laterality, no. (%)			<0.001
Unilateral	60 (54.1)	86.7 (76.5–96.9)
Bilateral	51 (45.9)	36.8 (21.5–52.1)
ENE, no. (%)			<0.001
Yes	28 (25.2)	30.7 (8.0–53.4)
No	83 (74.7)	71.1 (59.9–82.3)
Pelvic LNM, no. (%)			0.113
Yes	17 (15.3)	52.1 (22.7–81.5)
No	94 (84.7)	64.0 (52.8–75.2)
Adjuvant therapy, no. (%)			0.031
Yes	37 (33.3)	49.3 (29.1–69.5)
Adjuvant chemotherapy	28 (24.3)
Adjuvant radiotherapy alone	6 (5.4)
Adjuvant chemotherapy+radiotherapy	3 (2.7)
None	74 (66.7)	67.7 (55.4–80.0)
Number of LNMs, no. (%)			<0.001
1	26 (23.4)	89.6 (75.9–100.0)
2	22 (19.8)	89.6 (75.9–100.0)
3	25 (22.5)	48.8 (23.7–73.9)
⩾4	38 (34.2)	31.1 (13.2–49.1)
T, no. (%)			<0.001
⩽pT1	17 (15.3)	80.8 (56.1–100.0)
pT2	76 (68.4)	68.2 (56.4–80.0)
⩾pT3	18 (16.2)	19.6 (2.5–41.7)
G, no. (%)			0.144
G1	55 (49.5)	67.0 (52.9–81.1)
G2	41 (36.9)	62.3 (45.6–79.0)
G3	15 (13.5)	42.9 (9.6–76.2)
7th edition pN, no. (%)			<0.001
pN1	26 (23.4)	89.6 (75.9–100.0)
pN2	48 (43.2)	65.9 (51.0–80.8)
pN3	37 (33.3)	33.6 (13.4–53.8)
Modified pN, no. (%)			<0.001
pN1	40 (36.0)	90.7 (80.5–100.0)
pN2	28 (25.2)	60.5 (39.3–81.7)
pN3	43 (38.7)	31.4 (13.4–49.4)

Abbreviations: BMI=Body mass index; CI=confidence interval, ENE=extranodal extension; LN=lymph node; LNM=lymph node metastasis.